Lars W.
- Country
- Sweden
- Department
- Karolinska University Hospital, Department of Transplantation Surgery F82, 141 86 Huddinge
Research Overview
- A single-arm, multi-centre trial to evaluate efficacy and safety of imlifidase in highly sensitised children (1-17 years) receiving a kidney transplant with positive crossmatch against a living or deceased donor converted to negative after imlifidase treatment
- Frexalimab Versus Tacrolimus for Prevention of Kidney Graft Rejection in Adult Kidney Transplant Recipients
- Phase 2 Study on the Efficacy and Safety of Riliprubart in Antibody-Mediated Rejection Prevention and Treatment in Adult Kidney Transplant Recipients
Data & Insights
Has run more than one trial at 18 of 65 partner sites.
Specializations
Transplant Medicine
This investigator specializes in kidney transplantation and associated complications, with particular expertise in managing transplant rejection scenarios.
- Antibody-mediated rejection prevention and treatment
- Chronic active rejection management
- Graft function preservation
The investigator focuses on innovative therapeutic approaches in transplant medicine, including novel immunological interventions.
Pediatric Transplantation
Demonstrates specific interest in pediatric transplant medicine, particularly addressing challenges in highly sensitized young patients.
- Desensitization protocols
- Living and deceased donor compatibility
- Crossmatch conversion strategies
The research encompasses specialized treatments for complex pediatric transplant cases.
Immunological Therapeutics
Focuses on advanced immunological treatments in transplantation, including novel therapeutic agents and protocols.
- Immunomodulation therapies
- Anti-rejection medications
- Therapeutic antibodies
The investigator evaluates emerging immunological interventions for transplant recipients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.